New hope for Behcet's patients: drug TA-650 shows promise in rare disease trial
NCT ID NCT01532570
First seen Jan 07, 2026 · Last updated Jun 13, 2026 · Updated 31 times
Summary
This study tested a drug called TA-650 (similar to infliximab) in 18 people with Behcet's disease who had severe symptoms like brain or eye problems. The drug was given as an IV infusion at weeks 0, 2, and 6, then every 8 weeks up to week 46. The goal was to see if symptoms disappeared and inflammation improved. This is a disease-control treatment, not a cure, as ongoing medication may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHCET'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyusyu, Japan
-
Investigational site
Tōhoku, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.